ORIGINAL RESEARCH article
Front. Neurol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1670455
Effect of Hyperbaric Oxygen Therapy on Peripheral Blood Inflammatory Markers in Patients with Neuromyelitis Optica Spectrum Disorder: A Retrospective Cohort Study
Provisionally accepted
- 1The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- 2Liuzhou Workers Hospital, Liuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: Neuromyelitis optica spectrum disorder (NMOSD), an AQP4-IgG-mediated central nervous system demyelinating disease, is prone to recurrent disability. Although the anti-inflammatory and neuroprotective effects of hyperbaric oxygen therapy (HBOT) in neurological diseases have been reported, its immunological impact on NMOSD remains poorly understood. Objective: To evaluate the effect of HBOT on peripheral inflammatory markers in patients with NMOSD and explore its potential immunomodulatory role. Methods: This retrospective cohort study included 36 NMOSD patients diagnosed between January 2022 and December 2024, divided into an HBOT plus standard treatment group (n = 18) and a standard treatment-only group (n = 18). Peripheral blood samples were collected before and after treatment to assess the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte counts. Paired tests and ANCOVA (adjusted for baseline values) were used to compare within-group and between-group differences. Results: After a median of 12 HBOT sessions, the HBOT group showed a 31.78% increase in lymphocyte count (Δ = +0.41 ×10⁹/L, 95% CI: 0.05 to 0.77), and significant reductions in NLR by 18.98% (Δ = –0.52, 95% CI: –1.02 to –0.02) and PLR by 17.97% (Δ = –37.21, 95% CI: –69.15 to –5.27). After adjustment, the HBOT group demonstrated significantly greater improvements in NLR (–55.56%) and PLR (–22.79%) compared to the control group (both Bonferroni-corrected P < 0.01). Subgroup analysis revealed that patients with baseline NLR ≥ 3 benefited the most (interaction P = 0.038). No serious adverse events were observed. Conclusion: HBOT may help rebalance the immune system in NMOSD by increasing lymphocyte counts and reducing NLR and PLR, potentially contributing to immune modulation. These findings support the potential of HBOT as an adjunctive therapy for NMOSD, particularly in patients with a high inflammatory burden. Larger prospective studies are warranted to confirm its long-term efficacy and underlying mechanisms.
Keywords: hyperbaric oxygen therapy, Neuromyelitis optica spectrum disorder, Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Immunomodulation
Received: 21 Jul 2025; Accepted: 22 Oct 2025.
Copyright: © 2025 Pan, Mo, Wei, Luo and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuan Wu, nwuyuan@stu.gxmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.